Medoxa

Oxaliplatin, the active ingredient in Medoxa, is a platinum coordination complex (alkylating‑like agent) presented as an injection solution for intravenous use. It is employed in the treatment of colorectal cancer, both in adjuvant and metastatic stages, and is also incorporated into combination regimens for other solid tumours.

GNH USA supplies Medoxa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution, ensuring product integrity from manufacture to delivery.

Oxaliplatin is used in chemotherapy regimens targeting colorectal cancer and other solid tumours. - Colorectal cancer (adjuvant): Used after surgical resection to reduce risk of recurrence. - Colorectal cancer (metastatic): Used to shrink or control tumor growth in advanced disease. - Other solid tumours (combination therapy): Contributes to cytotoxic effect when combined with other agents in various solid tumour protocols.

Oxaliplatin may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea and vomiting: typical chemotherapy‑related gastrointestinal upset. - Diarrhea: may be mild to moderate. - Peripheral neuropathy: tingling or numbness in hands and feet. - Fatigue: generalized tiredness. - Thrombocytopenia: reduced platelet count. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: including anaphylaxis. - Acute hemolytic anemia: rare immune‑mediated destruction of red cells. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Severe neutropenia: marked decrease in neutrophils increasing infection risk.

When using Oxaliplatin, clinicians should observe specific safety measures to minimize risks. - Renal function: assess baseline creatinine and monitor during therapy. - Neuropathy monitoring: evaluate sensory changes before each cycle. - Hematologic assessment: perform complete blood counts regularly. - Hypersensitivity risk: be prepared to manage infusion reactions. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal or neonatal risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Oxaliplatin can interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Aminoglycoside antibiotics: may increase neurotoxicity. - Concomitant use with other platinum agents: additive renal and hematologic toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): potential for enhanced bleeding due to thrombocytopenia. - NSAIDs: may exacerbate renal impairment. - High‑dose vitamin C: may reduce platinum binding to DNA. - Diuretics: can affect electrolyte balance and renal clearance.